Which has higher valuation & earnings, ELDN or IMMX?

Immix Biopharma is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A Immix Biopharma N/A N/A -$29.44M -$0.88 N/A

Is ELDN or IMMX more profitable?

Immix Biopharma's return on equity of -38.44% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% Immix Biopharma N/A -38.44% -34.72%

Does the media favor ELDN or IMMX?

In the previous week, Immix Biopharma had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Immix Biopharma and 2 mentions for Eledon Pharmaceuticals. Immix Biopharma's average media sentiment score of 1.15 beat Eledon Pharmaceuticals' score of 0.94 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, CLYM or ELDN?

Climb Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.83 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A

Is CLYM or ELDN more profitable?

Climb Bio's return on equity of -31.79% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.79% -30.79% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media refer more to CLYM or ELDN?

In the previous week, Climb Bio had 8 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 10 mentions for Climb Bio and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.94 beat Climb Bio's score of 0.90 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ANNX or ELDN?

Annexon is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A

Is ANNX or ELDN more profitable?

Annexon's return on equity of -106.15% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media refer more to ANNX or ELDN?

In the previous week, Annexon had 3 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Annexon and 2 mentions for Eledon Pharmaceuticals. Annexon's average media sentiment score of 1.07 beat Eledon Pharmaceuticals' score of 0.94 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RIGL or ELDN?

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 0.94 beat Rigel Pharmaceuticals' score of 0.94 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELDN or ACRS?

In the previous week, Aclaris Therapeutics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.94 beat Aclaris Therapeutics' score of 0.59 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eledon Pharmaceuticals (ELDN) Competitors

$2.78 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.78 +0.01 (+0.18%)

As of 09/11/2026 07:30 PM Eastern

Compare

ELDN vs. IMMX, CLYM, ANNX, RIGL, and ACRS

Should you buy Eledon Pharmaceuticals stock or one of its competitors? Eledon Pharmaceuticals's main competitors and comparable companies include Immix Biopharma (IMMX), Climb Bio (CLYM), Annexon (ANNX), Rigel Pharmaceuticals (RIGL), and Aclaris Therapeutics (ACRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eledon Pharmaceuticals compare to Immix Biopharma?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Immix Biopharma had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Immix Biopharma and 2 mentions for Eledon Pharmaceuticals. Immix Biopharma's average media sentiment score of 1.15 beat Eledon Pharmaceuticals' score of 0.94 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 259.71%. Immix Biopharma has a consensus price target of $21.29, indicating a potential upside of 75.34%. Given Eledon Pharmaceuticals' higher probable upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Immix Biopharma's return on equity of -38.44% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
Immix Biopharma	N/A	-38.44%	-34.72%

Immix Biopharma is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 30.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Summary

Immix Biopharma beats Eledon Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Climb Bio's return on equity of -31.79% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Climb Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Climb Bio presently has a consensus price target of $26.92, suggesting a potential upside of 88.93%. Eledon Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 259.71%. Given Eledon Pharmaceuticals' higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Climb Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

In the previous week, Climb Bio had 8 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 10 mentions for Climb Bio and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.94 beat Climb Bio's score of 0.90 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Climb Bio beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Annexon?

Annexon (NASDAQ:ANNX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Annexon is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

In the previous week, Annexon had 3 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Annexon and 2 mentions for Eledon Pharmaceuticals. Annexon's average media sentiment score of 1.07 beat Eledon Pharmaceuticals' score of 0.94 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Annexon has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Annexon's return on equity of -106.15% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Annexon currently has a consensus target price of $15.14, suggesting a potential upside of 284.34%. Eledon Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 259.71%. Given Annexon's stronger consensus rating and higher possible upside, analysts plainly believe Annexon is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Annexon beats Eledon Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Rigel Pharmaceuticals presently has a consensus price target of $59.00, suggesting a potential upside of 24.89%. Eledon Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 259.71%. Given Eledon Pharmaceuticals' higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 0.94 beat Rigel Pharmaceuticals' score of 0.94 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Eledon Pharmaceuticals' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Rigel Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Rigel Pharmaceuticals has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.97	$367.02M	$16.32	2.89
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

Summary

Rigel Pharmaceuticals beats Eledon Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Aclaris Therapeutics?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 259.71%. Aclaris Therapeutics has a consensus target price of $11.33, suggesting a potential upside of 113.03%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Eledon Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Eledon Pharmaceuticals has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
Aclaris Therapeutics	$7.83M	95.00	-$64.92M	-$0.58	N/A

In the previous week, Aclaris Therapeutics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.94 beat Aclaris Therapeutics' score of 0.59 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Eledon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$225.91M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-3.05	8.41	214.39	20.85
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	2.06	15.12	10.33	6.21
Net Income	-$45.62M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-7.95%	-4.34%	-3.32%	-2.35%
1 Month Performance	-24.86%	0.54%	-0.53%	-3.23%
1 Year Performance	14.88%	40.74%	23.51%	8.79%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	1.5957 of 5 stars	$2.78 flat	$10.00 +259.7%	+14.9%	$225.91M	N/A	N/A	10
IMMX Immix Biopharma	3.5621 of 5 stars	$13.25 -4.7%	$21.29 +60.6%	+478.1%	$947.91M	N/A	N/A	9	Positive News
CLYM Climb Bio	3.1314 of 5 stars	$15.90 +2.4%	$26.92 +69.3%	+533.3%	$913.30M	N/A	N/A	9	Analyst Forecast
ANNX Annexon	2.6169 of 5 stars	$4.67 -4.1%	$15.14 +224.3%	+62.8%	$885.34M	N/A	N/A	60	Positive News
RIGL Rigel Pharmaceuticals	4.4701 of 5 stars	$47.37 -2.7%	$59.00 +24.6%	+24.4%	$876.35M	$294.28M	2.90	160	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. IMMX, CLYM, ANNX, RIGL, and ACRS

How does Eledon Pharmaceuticals compare to Immix Biopharma?

Summary

How does Eledon Pharmaceuticals compare to Climb Bio?

Summary

How does Eledon Pharmaceuticals compare to Annexon?

Summary

How does Eledon Pharmaceuticals compare to Rigel Pharmaceuticals?

Summary

How does Eledon Pharmaceuticals compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. IMMX, CLYM, ANNX, RIGL, and ACRS

How does Eledon Pharmaceuticals compare to Immix Biopharma?

Does the media favor ELDN or IMMX?

Do analysts recommend ELDN or IMMX?

Is ELDN or IMMX more profitable?

Which has higher valuation & earnings, ELDN or IMMX?

Do institutionals and insiders hold more shares of ELDN or IMMX?

Which has more risk & volatility, ELDN or IMMX?

Summary

How does Eledon Pharmaceuticals compare to Climb Bio?

Is CLYM or ELDN more profitable?

Which has more risk & volatility, CLYM or ELDN?

Do analysts rate CLYM or ELDN?

Which has stronger valuation and earnings, CLYM or ELDN?

Does the media refer more to CLYM or ELDN?

Do institutionals & insiders have more ownership in CLYM or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Annexon?

Which has better earnings & valuation, ANNX or ELDN?

Does the media refer more to ANNX or ELDN?

Do institutionals and insiders have more ownership in ANNX or ELDN?

Which has more risk and volatility, ANNX or ELDN?

Is ANNX or ELDN more profitable?

Do analysts rate ANNX or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Rigel Pharmaceuticals?

Do analysts rate RIGL or ELDN?

Does the media refer more to RIGL or ELDN?

Do insiders and institutionals have more ownership in RIGL or ELDN?

Is RIGL or ELDN more profitable?

Which has more volatility and risk, RIGL or ELDN?

Which has higher earnings and valuation, RIGL or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Aclaris Therapeutics?

Is ELDN or ACRS more profitable?

Do insiders & institutionals hold more shares of ELDN or ACRS?

Do analysts rate ELDN or ACRS?

Which has preferable valuation and earnings, ELDN or ACRS?

Does the media refer more to ELDN or ACRS?

Which has more risk & volatility, ELDN or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools